S. No.
|
Variables
|
Total
|
Parkin Expressiona
|
P valueb
|
OR (95%CI)
|
---|
Positive
|
Negative
|
---|
1
|
Age (Years)
|
< 50
|
30
|
9 (30)
|
21 (70)
|
0.832
|
1.1255(0.4738–2.6737)
|
≥50
|
126
|
41 (33)
|
85 (67)
|
2
|
Weight (Kg)
|
< 60
|
75
|
26 (35)
|
49 (65)
|
0.607
|
0.7935 (0.4046–1.5562)
|
≥60
|
81
|
24 (30)
|
57 (70)
|
3
|
Tumour size (cm)
|
< 4’
|
73
|
29 (40)
|
44 (60)
|
0.060
|
0.5139 (0. 2599–1.0161)
|
≥4
|
83
|
21 (25)
|
62 (75)
|
4
|
Clinical Stage
|
I + II
|
88
|
29 (33)
|
59 (67)
|
0.863
|
0.9090 (0.4606–1.7941)
|
III + IV
|
68
|
21 (31)
|
47 (69)
|
5
|
Histologicalc grade
|
WD
|
54
|
27 (50)
|
27 (50)
|
0.0001*
|
0.2911 (0.1435–0.5906)
|
MD + PD
|
102
|
23 (22)
|
79 (78)
|
6
|
Lymph Node
|
Negative
|
81
|
39 (48)
|
42 (52)
|
< 0.0001*
|
0.1851 (0.0854–0.4014)
|
Positive
|
75
|
11 (15)
|
64 (85)
|
7
|
Menopause
|
Pre
|
38
|
18 (47)
|
20 (53)
|
0.028*
|
0.4134 (0.1943–0.8797)
|
Post
|
118
|
32 (27)
|
86 (73)
|
8
|
ERd
|
Negative
|
81
|
23 (28)
|
58 (72)
|
0.391
|
1.9438 (0.0190–3.7081)
|
Positive
|
75
|
27 (36)
|
48 (64)
|
9
|
PRe
|
Negative
|
103
|
32 (31)
|
71 (69)
|
0.721
|
1.1411 (0.5637–2.3099)
|
Positive
|
53
|
18 (34)
|
35 (66)
|
10
|
Her-2f
|
Negative
|
111
|
36 (32)
|
75 (68)
|
1.000
|
0.9409 (0.4463–1.9835)
|
Positive
|
45
|
14 (31)
|
31 (69)
|
11
|
TNBCg
|
No
|
106
|
42 (40)
|
64 (60)
|
0.003*
|
0.2902 (0.1240–0.6793)
|
Yes
|
50
|
8 (16)
|
42 (84)
|
- a Protein expression through IHC (Immunohistochemistry)
- b Fisher’s exact test, *Significant Correlation (P < 0.05)
- c WD Well differentiated, MD Moderately differentiated, PD Poorly differentiated
- d Estrogen receptor
- e Progesterone receptor
- f human epidermal growth factor receptor 2
- g Triple Negative breast cancer